Description: Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Home Page: www.neovasc.com
NVCN Technical Analysis
13562 Maycrest Way
Richmond,
BC
V6V 2J7
Canada
Phone:
604 270 4344
Officers
| Name | Title |
|---|---|
| Mr. Fredericus A. Colen | Pres, CEO & Director |
| Mr. Christopher Clark B.A., BA (Honours), C.A., CA, PgD | CFO & Corp. Sec. |
| Mr. William Reed Little | Chief Operating Officer |
| Mr. John Christopher Panton | Chief Quality Officer |
| Sarah Marie-Hodgson Gallagher | VP of Clinical Affairs |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7945 |
| Price-to-Sales TTM: | 12.4564 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 49 |